Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika AC, Morse MA, Lyerly HK, Hartman ZC.

Clin Cancer Res. 2019 May 1;25(9):2725-2736. doi: 10.1158/1078-0432.CCR-18-3102. Epub 2019 Jan 11.

PMID:
30635338
2.

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.

Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, Diniz MA, Spector N, Clay TM, Chen W, Morse MA, Lyerly HK.

Breast Cancer Res. 2018 Aug 9;20(1):90. doi: 10.1186/s13058-018-1023-x.

3.

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK.

Ann Surg. 2013 Dec;258(6):879-86. doi: 10.1097/SLA.0b013e318292919e.

4.

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.

Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK.

Cancer Immunol Immunother. 2013 Aug;62(8):1293-301. doi: 10.1007/s00262-013-1400-3. Epub 2013 Apr 30.

5.

Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

Ren XR, Wei J, Lei G, Wang J, Lu J, Xia W, Spector N, Barak LS, Clay TM, Osada T, Hamilton E, Blackwell K, Hobeika AC, Morse MA, Lyerly HK, Chen W.

Breast Cancer Res. 2012 Jun 7;14(3):R89.

6.

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA.

J Transl Med. 2012 Feb 10;10:28. doi: 10.1186/1479-5876-10-28. Erratum in: J Transl Med. 2013;11:82. Morse, Michael A [added].

7.

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R.

Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7.

8.

Depletion of human regulatory T cells.

Hobeika AC, Morse MA, Osada T, Peplinski S, Lyerly HK, Clay TM.

Methods Mol Biol. 2011;707:219-31. doi: 10.1007/978-1-61737-979-6_14.

PMID:
21287338
9.

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK.

J Clin Invest. 2010 Sep;120(9):3234-41. doi: 10.1172/JCI42672. Epub 2010 Aug 2.

10.

Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM.

Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995.

11.

Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.

Sun B, Kulis MD, Young SP, Hobeika AC, Li S, Bird A, Zhang H, Li Y, Clay TM, Burks W, Kishnani PS, Koeberl DD.

Mol Ther. 2010 Feb;18(2):353-60. doi: 10.1038/mt.2009.195. Epub 2009 Aug 18.

12.

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM.

Blood. 2008 Aug 1;112(3):610-8. doi: 10.1182/blood-2008-01-135319. Epub 2008 Jun 2.

13.

Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.

Hobeika A, Osada T, Serra D, Peplinski S, Hanson K, Tanaka Y, Niedzwiecki D, Chao N, Rizzieri D, Lyerly H, Clay T, Morse M.

Cytotherapy. 2008;10(3):289-302. doi: 10.1080/14653240801927040.

PMID:
18418774
14.

Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.

Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA.

Expert Opin Biol Ther. 2007 Apr;7(4):449-60. Review.

PMID:
17373897
15.

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.

Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.

Clin Cancer Res. 2005 Apr 15;11(8):3017-24.

16.

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM.

J Immunother. 2005 Jan-Feb;28(1):63-72.

PMID:
15614046
17.

Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.

Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK.

Cancer Invest. 2003 Jun;21(3):341-9.

PMID:
12901279
18.

Proteomics for monitoring immune responses to cancer vaccines.

Mosca PJ, Lyerly HK, Ching CD, Hobeika AC, Clay TM, Morse MA.

Curr Opin Mol Ther. 2003 Feb;5(1):39-43. Review.

PMID:
12669469
19.

Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.

Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA.

J Leukoc Biol. 2002 Sep;72(3):546-53.

PMID:
12223523
20.

Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.

Morse MA, Rizzieri D, Stenzel TT, Hobeika AC, Vredenburgh JJ, Chao NJ, Clay TM, Mosca PJ, Lyerly HK.

J Hematother Stem Cell Res. 2002 Aug;11(4):659-68.

PMID:
12201954
21.

Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer.

Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM.

Int J Cancer. 2001 Dec 15;94(6):834-41.

22.

Surrogate markers of response to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK.

Expert Opin Biol Ther. 2001 Mar;1(2):153-8.

PMID:
11727526
23.

Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA.

Crit Rev Immunol. 2001;21(1-3):287-97. Review.

PMID:
11642610
24.

Superantigens: the good, the bad, and the ugly.

Torres BA, Kominsky S, Perrin GQ, Hobeika AC, Johnson HM.

Exp Biol Med (Maywood). 2001 Mar;226(3):164-76. Review.

PMID:
11361034
25.

Assays for monitoring cellular immune responses to active immunotherapy of cancer.

Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA.

Clin Cancer Res. 2001 May;7(5):1127-35. Review.

26.

Monitoring cellular immune responses to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK.

Curr Opin Mol Ther. 2001 Feb;3(1):45-52. Review.

PMID:
11249731
27.

Direct detection of cellular immune responses to cancer vaccines.

Mosca PJ, Hobeika AC, Clay TM, Morse MA, Lyerly HK.

Surgery. 2001 Mar;129(3):248-54. Review.

PMID:
11231452
28.
29.

Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.

Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM.

Cancer Res. 2000 Jul 15;60(14):3904-8.

30.

IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis.

Hobeika AC, Etienne W, Torres BA, Johnson HM, Subramaniam PS.

J Interferon Cytokine Res. 1999 Dec;19(12):1351-61.

PMID:
10638704
31.

IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1.

Kominsky S, Johnson HM, Bryan G, Tanabe T, Hobeika AC, Subramaniam PS, Torres B.

Oncogene. 1998 Dec 10;17(23):2973-9.

32.

IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential.

Hobeika AC, Etienne W, Cruz PE, Subramaniam PS, Johnson HM.

Int J Cancer. 1998 Jul 3;77(1):138-45.

33.
34.

IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells.

Hobeika AC, Subramaniam PS, Johnson HM.

Oncogene. 1997 Mar 13;14(10):1165-70.

35.

A neutralizing epitope of the superantigen SEA has agonist activity on T cells.

Hobeika AC, Johnson HM.

Biochem Biophys Res Commun. 1996 Jun 25;223(3):565-71.

PMID:
8687436
36.
37.

Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigen.

Soos JM, Hobeika AC, Butfiloski EJ, Schiffenbauer J, Johnson HM.

Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6082-6.

Supplemental Content

Loading ...
Support Center